Literature DB >> 10223956

Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae.

K L Bergman1, K M Olsen, T E Peddicord, P D Fey, M E Rupp.   

Abstract

The antimicrobial activity of concentrations of selected macrolides found in epithelial cell lining fluid was investigated. Clarithromycin demonstrated greater potency and a significantly longer postantibiotic effect (PAE) than azithromycin against Streptococcus pneumoniae. Azithromycin displayed greater potency, faster killing, and a longer PAE than clarithromycin against Haemophilus influenzae. Drug concentrations in epithelial cell lining fluid similar to those found in tissue did not improve the synergistic potential of 14-hydroxy-clarithromycin and indicate that a maximal PAE may exist despite increasing concentrations of drug.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10223956      PMCID： PMC89263     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association.

Authors:  M S Niederman; J B Bass; G D Campbell; A M Fein; R F Grossman; L A Mandell; T J Marrie; G A Sarosi; A Torres; V L Yu
Journal:  Am Rev Respir Dis       Date:  1993-11

2.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  Penetration of clarithromycin into lung tissues from patients undergoing lung resection.

Authors:  D N Fish; M H Gotfried; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

6.  The levels of clarithromycin and its 14-hydroxy metabolite in the lung.

Authors:  D Honeybourne; F Kees; J M Andrews; D Baldwin; R Wise
Journal:  Eur Respir J       Date:  1994-07       Impact factor: 16.671

7.  Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.

Authors:  J E Conte; J A Golden; S Duncan; E McKenna; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

8.  Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.

Authors:  K J Walker; A J Larsson; R A Zabinski; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.

Authors:  H Dabernat; C Delmas; M Seguy; J B Fourtillan; J Girault; M B Lareng
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

10.  Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens.

Authors:  J W Gu; B E Scully; H C Neu
Journal:  J Clin Pharmacol       Date:  1991-12       Impact factor: 3.126
View more
  4 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 2.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

Review 3.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Antibacterial and immunomodulatory activities of insect defensins-DLP2 and DLP4 against multidrug-resistant Staphylococcus aureus.

Authors:  Zhanzhan Li; Ruoyu Mao; Da Teng; Ya Hao; Huixian Chen; Xiumin Wang; Xiao Wang; Na Yang; Jianhua Wang
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.